Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses… Read more
Altamira Therapeutics Ltd (CYTO) - Total Liabilities
Latest total liabilities as of March 2024: $1.24 Million USD
Based on the latest financial reports, Altamira Therapeutics Ltd (CYTO) has total liabilities worth $1.24 Million USD as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Altamira Therapeutics Ltd - Total Liabilities Trend (2011–2023)
This chart illustrates how Altamira Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Altamira Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Altamira Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BITTIUM (JOT.SG)
STU:JOT
|
Germany | €50.07 Million |
|
AB Snaige
STU:ZS4
|
Germany | €21.51 Million |
|
Klimat X Developments Inc.
V:KLX
|
Canada | CA$8.82 Million |
|
Siemens Energy India Limited
NSE:ENRIN
|
India | ₹51.64 Billion |
|
MITSUI O.S.K.LINES - Dusseldorf Stock Exchang
DU:MILA
|
Germany | €1.75 Trillion |
|
Ginegar
TA:GNGR
|
Israel | ILA476.69 Million |
|
CENTURY ALUMINUM
BE:EY3
|
Germany | €1.27 Billion |
Liability Composition Analysis (2011–2023)
This chart breaks down Altamira Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Altamira Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Altamira Therapeutics Ltd (2011–2023)
The table below shows the annual total liabilities of Altamira Therapeutics Ltd from 2011 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $1.24 Million | -91.55% |
| 2022-12-31 | $14.62 Million | +138.30% |
| 2021-12-31 | $6.13 Million | +52.23% |
| 2020-12-31 | $4.03 Million | +26.32% |
| 2019-12-31 | $3.19 Million | -48.77% |
| 2018-12-31 | $6.23 Million | -68.85% |
| 2017-12-31 | $19.99 Million | -7.10% |
| 2016-12-31 | $21.52 Million | +166.57% |
| 2015-12-31 | $8.07 Million | +29.97% |
| 2014-12-31 | $6.21 Million | -63.93% |
| 2013-12-31 | $17.22 Million | +1451.51% |
| 2012-12-31 | $1.11 Million | +24.45% |
| 2011-12-31 | $891.77K | -- |